EW Q2 2025 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q2 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.5B+10.6% YoY

Gross Profit

$1.2B77.6% margin

Operating Income

$431M28.1% margin

Net Income

$330M21.5% margin

EPS (Diluted)

$0.56

QoQ Revenue Growth

+8.5%

Cash Flow

Operating Cash Flow

$290M

Free Cash Flow

$241M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$13.5B

Total Liabilities

$2.9B

Stockholders' Equity

$10.5B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.4B	+10.6%
Gross Profit	$1.2B	$1.1B	+9.3%
Operating Income	$431M	$365M	+18.2%
Net Income	$330M	$364M	-9.3%

Revenue Segments

Transcatheter Heart Valves

$1.1B74%

Surgical Heart Valve Therapy

$267M17%

Transcatheter Mitral And Tricuspid Therapies

$135M9%

Geographic Segments

UNITED STATES

$890M58%

Europe

$378M25%

Rest of World

$169M11%

JAPAN

$95M6%